Iñigo Bermejo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1967130/publications.pdf

Version: 2024-02-01

1162367 996533 26 245 8 15 citations g-index h-index papers 27 27 27 471 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Artificial intelligenceâ€based clinical decision support in modern medical physics: Selection, acceptance, commissioning, and quality assurance. Medical Physics, 2020, 47, e228-e235.	1.6	64
2	A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Health Technology Assessment, 2017, 21, 1-170.	1.3	26
3	Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 131-144.	1.7	21
4	Computer-assisted CI fitting: Is the learning capacity of the intelligent agent FOX beneficial for speech understanding?. Cochlear Implants International, 2017, 18, 198-206.	0.5	19
5	Systematic review of radiomic biomarkers for predicting immune checkpoint inhibitor treatment outcomes. Methods, 2021, 188, 61-72.	1.9	16
6	Markov Influence Diagrams. Medical Decision Making, 2017, 37, 183-195.	1.2	12
7	Decision analysis networks. International Journal of Approximate Reasoning, 2018, 96, 1-17.	1.9	12
8	Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020, 55, 1473-1475.	1.3	9
9	Replicating Health Economic Models: Firm Foundations or a House of Cards?. Pharmacoeconomics, 2017, 35, 1113-1121.	1.7	8
10	Generative models improve radiomics performance in different tasks and different datasets: An experimental study. Physica Medica, 2022, 98, 11-17.	0.4	8
11	Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 769-778.	1.7	7
12	Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 1063-1072.	1.7	5
13	Adalimumab for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology, 2019, 103, 1633-1638.	2.1	5
14	Dexamethasone implant for non-infectious uveitis: is it cost-effective?. British Journal of Ophthalmology, 2019, 103, 1639-1644.	2.1	4
15	Predicting Lung Cancer Survival Using Probabilistic Reclassification of TNM Editions With a Bayesian Network. JCO Clinical Cancer Informatics, 2020, 4, 436-443.	1.0	4
16	External Validation of a Bayesian Network for Error Detection in Radiotherapy Plans. IEEE Transactions on Radiation and Plasma Medical Sciences, 2022, 6, 200-206.	2.7	4
17	A Probabilistic Graphical Model for Tuning Cochlear Implants. Lecture Notes in Computer Science, 2013, , 150-155.	1.0	4
18	Bayesian network structure for predicting local tumor recurrence in rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery. Physics and Imaging in Radiation Oncology, 2022, 22, 1-7.	1,2	4

#	Article	IF	CITATIONS
19	Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 1427-1437.	1.7	3
20	Feasibility of Privacy-Preserving Federated Deep Learning on Medical Images. International Journal of Radiation Oncology Biology Physics, 2020, 108, e778.	0.4	3
21	Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 1141-1151.	1.7	2
22	Response to ‴Comment on "Replicating Health Economic Models: Firm Foundations or a House of Cards?â€â€™. Pharmacoeconomics, 2017, 35, 1189-1190.	1.7	2
23	Evaluation of Markov Models with Discontinuities. Medical Decision Making, 2019, 39, 414-420.	1.2	2
24	OP131 Cost-Effectiveness Of Dexamethasone And Adalimumab For Uveitis. International Journal of Technology Assessment in Health Care, 2017, 33, 60-61.	0.2	1
25	Advanced Algorithms for Medical Decision Analysis. Implementation in OpenMarkov. Lecture Notes in Computer Science, 2017, , 356-360.	1.0	О
26	Using clinical prediction models to personalise lifestyle interventions for cardiovascular disease prevention: A systematic literature review. Preventive Medicine Reports, 2022, 25, 101672.	0.8	0